Perivascular Niche–Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment
Trastuzumab deruxtecan (T-DXd) is a transformative HER2-targeting antibody-drug conjugate (ADC) for treating breast cancer. Unfortunately, T-DXd has also been implicated in causing fatal interstitial lung disease (ILD) in multiple clinical trials. A better understanding of the mechanistic basis of these ADC-induced adverse effects could enable development of strategies to prevent or treat T-DXd-related ILD. In this study, we determined that T-DXd-induced ILD represents an off-target adverse event rather than an on-target off-tumor adverse event. To further investigate this phenomenon, an immunocompetent murine model that recapitulates T-DXd-induced ILD events was developed, facilitating in-depth mechanistic studies. Single-cell RNA sequencing in this model implicated alveolar macrophages (AM) as the primary cell type impacted by T-DXd in the lung microenvironment. Intravital microscopy further revealed that AMs resident in perivascular niches directly engulfed blood-circulating T-DXd via Fc-FcγR engagement. This Fc-FcγR interaction with T-DXd triggered a phenotypic shift in AMs from an immunosuppressive to a pro-ILD state, characterized by inflammation and immune activation, mediated through the SPP1 pathways. Finally, mitigating nonspecific T-DXd uptake in the lung by preconditioning perivascular AMs with IgG1 or the parental antibody of T-DXd significantly reduced unintended ADC absorption. These findings elucidate a mechanism by which T-DXd ignites the lung immune microenvironment and underscore the importance of off-target endocytosis by innate immune cells in the development of ADC-related toxicities. Significance: Preconditioning the perivascular niche can prevent lung inflammation induced by antibody-drug conjugate phagocytosis by alveolar macrophages and subsequent SPP1high macrophage differentiation, providing a clinically viable strategy for mitigating interstitial lung disease.
Authors
- Lan Wang (ORCID: https://orcid.org/0000-0001-5364-0931)
- Jianmin Fang (ORCID: https://orcid.org/0000-0002-4332-4967)
- Jieer Ying (ORCID: https://orcid.org/0000-0001-9452-1242)
- Yun Xing
- Takaya Shimura (ORCID: https://orcid.org/0000-0002-6048-0021)
- Xuefei Tian (ORCID: https://orcid.org/0009-0008-1739-5084)
- Mengyang Fan (ORCID: https://orcid.org/0000-0002-0871-8792)
- Ziwen Zhang (ORCID: https://orcid.org/0009-0004-3062-9050)
- Teng Yang (ORCID: https://orcid.org/0009-0009-0119-5763)
- Peng Guo (ORCID: https://orcid.org/0009-0004-8215-7673)
- Yuxuan Yang
- Xiangdong Cheng (ORCID: https://orcid.org/0000-0002-5099-490X)
- Ye Lu (ORCID: https://orcid.org/0000-0002-8729-0316)
- Jiayu Zhu (ORCID: https://orcid.org/0009-0001-3552-3755)
- Meng Li (ORCID: https://orcid.org/0009-0003-1444-8375)
- Yuchao Zhang (ORCID: https://orcid.org/0009-0003-2029-9871)
- Zhiwei Cao (ORCID: https://orcid.org/0000-0003-1165-1928)
- Qing Wei (ORCID: https://orcid.org/0000-0002-8651-3012)
- Xiu Zhu (ORCID: https://orcid.org/0000-0002-5945-0941)
- Y. Li (ORCID: https://orcid.org/0000-0003-0930-2649)
- Fei Wang (ORCID: https://orcid.org/0009-0008-8513-6391)
- Xu Xue (ORCID: https://orcid.org/0009-0008-0989-0464)
- Chuanfei Yu (ORCID: https://orcid.org/0000-0002-7583-4945)
Institutions
- Zhejiang Chinese Medical University (CN)
- Tongji University (CN)
- University of Science and Technology of China (CN)
- Tianjin University (CN)
- Zhejiang University of Science and Technology (CN)
- Tianjin Foreign Studies University (CN)
- National Medical Products Administration (CN)
- Fudan University (CN)
- Nagoya City University (JP)
- Zhejiang Cancer Hospital (CN)
- Peer Intelligence Technology (China) (CN)
- Hangzhou Academy of Agricultural Sciences (CN)
- National Institutes for Food and Drug Control (CN)
- University of Chinese Academy of Sciences (CN)
- Hangzhou Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1158/0008-5472.can-24-2021
- Citations
- 11
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 16.70
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Natural Science Foundation of Zhejiang Province